Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625775 · ClinicalTrials.gov registry record · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
A Phase 1 study of Metastatic Breast Cancer and Solid Tumor, Adult, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 392
- Enrollment target
- 20
- Study locations
NCT06625775: Recruiting Phase 1 study of Metastatic Breast Cancer and Solid Tumor, Adult, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).
NCT06625775 is a Phase 1 study of Metastatic Breast Cancer and Solid Tumor, Adult that is actively recruiting participants, run by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics). The registered enrollment target is 392 participants, above the 202-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (94% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06625775, a Phase 1 study of Metastatic Breast Cancer and Solid Tumor, Adult, is actively recruiting participants, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 392 participants
- Enrollment target
- 20
- Study locations
Study Summary
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Fulvestrant
- DRUG Ribociclib
- DRUG FOLFOX
- DRUG BBO-10203
Study Locations (20)
Texas
- SCRI at Mary Crowley - Dallas
- University of Texas Southwestern Medical Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
- University of Texas San Antonio (UTSA) - San Antonio
California
- University of California Los Angeles - Los Angeles
- University of California San Diego Moores Cancer Center - San Diego
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Insitute - Boston
Missouri
- St. Lukes Hospital of Kansas City - Kansas City
- Washington University School of Medicine - St Louis
New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- Moffitt Cancer Center - Tampa
Indiana
- Indiana University Simon Comprehensive Cancer Center - Indianapolis
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2028-11 |
| Phase | Phase 1 |
What NCT06625775 shows while recruiting
NCT06625775 is an interventional study that assigns participants to a tested intervention. The registered 392 participants enrollment target is mid-sized for trials with a published cap, above the 202-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (94% higher).
The record links to 10 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT06625775 names 20 study sites across 12 states, led by Texas, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06625775 about?
NCT06625775 is a clinical study titled "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors". First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
What is the current status of trial NCT06625775?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 392 participants. The study started on 2024-10-29. Estimated completion is 2028-11.
What conditions does trial NCT06625775 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Solid Tumor, Adult, Metastatic Colorectal Cancer, Advanced Breast Cancer, HER2-positive Metastatic Breast Cancer.
What interventions are being tested in trial NCT06625775?
The interventions under investigation include: Trastuzumab (DRUG), Fulvestrant (DRUG), Ribociclib (DRUG), FOLFOX (DRUG), BBO-10203 (DRUG).
Who is sponsoring clinical trial NCT06625775?
This trial is sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625775 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06625775's enrollment target sits among peer trials
392 18th of 139 higher than 122 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI